Moderna, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stéphane Bancel
- Full Time Employees
- 4,700
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 325 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Dec 7, 2018
- CIK
- 0001682852
- Website
- modernatx.com
- Similar Companies
- Business
- Moderna, Inc. (MRNA) develops and commercializes messenger RNA (mRNA) medicines and vaccines for infectious diseases, oncology, rare diseases, and other therapeutic areas; its core products include Spikevax (mRNA-1273), the COVID-19 vaccine approved for individuals 18 years and older; mRESVIA (mRNA-1345), the respiratory syncytial virus (RSV) vaccine for adults 60 years and older approved in the U.S., Europe, Canada, and Qatar; and mNEXSPIKE (mRNA-1283), the next-generation COVID-19 vaccine approved in the U.S.; the company advances a pipeline of over 45 development programs, including seasonal influenza and combination flu/COVID vaccines, cytomegalovirus vaccine candidates, individualized neoantigen therapies (INTs) such as intismeran autogene for oncology, and rare disease treatments targeting conditions like glycogen storage disease type 1a, with 36 ongoing clinical trials encompassing nine Phase 2 and Phase 3 oncology studies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with manufacturing facilities in Norwood, Massachusetts, Moderna operates globally, partnering with governments and organizations in the U.S., UK, Canada, Australia, and Europe to support research, development, and commercial supply. Recent developments include closing a five-year $1.5 billion non-dilutive term loan facility with Ares Management Credit Funds in November 2025 to enhance liquidity to $7.1-7.6 billion; launching a three-year business strategy targeting up to 10% revenue growth in 2026 through geographic expansion and new product launches, aiming to grow its seasonal vaccine franchise from three to six approved products by 2028; investing $140 million to expand its Norwood facility for onshoring drug product capabilities, completing end-to-end domestic mRNA manufacturing; and discontinuing three pipeline assets—mRNA-1010 (seasonal influenza), mRNA-1083 (influenza/COVID combo), and mRNA-3745 (glycogen storage disease type 1a)—to prioritize high-impact programs amid cost management.
MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback
Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript
Moderna Q2: Weak Revenue, Strong Pipeline - Here's What Matters Now
Moderna Q2 Earnings Call Highlights
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
Optimistic Tech Earnings Lift Stock Futures
Moderna Narrows Loss, Says New Norovirus Vaccine Didn't Meet Expectations
Breakfast News: AMZN Has Proof, Apple Has Problems
Is Moderna Inc (MRNA) Overvalued After Q2 Earnings Report? EPS of -$1.97 Misses Estimate, Revenue of $145 Million Slightly Beats
Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?
Moderna misses quarterly revenue estimates on COVID vaccine weakness
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?
3 Biotech Stocks With Massive Upside to Buy Before August Starts
Dimensional Fund Advisors LP Buys 343,216 Shares of Moderna, Inc. $MRNA
2 Major Reasons to Buy Moderna Stock Before July 31
Moderna (MRNA) Laps the Stock Market: Here's Why
After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?
Moderna: A Stock to Watch or a Risky Bet?
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know